Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
On January 24, 2025, Dr. Reddy’s Laboratories announced the publication of their unaudited financial results for the quarter ending December 31, 2024. These results were advertised in the Business Standard and Andhra Prabha newspapers, reflecting the company’s commitment to transparency and regulatory compliance as per the Securities and Exchange Board of India’s guidelines. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance during that period.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent player in the pharmaceutical industry, primarily engaged in the development and distribution of generic medicines, active pharmaceutical ingredients, and over-the-counter products, with a focus on both emerging and developed markets.
YTD Price Performance: -9.70%
Average Trading Volume: 1,485,577
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $12.44B
See more data about RDY stock on TipRanks’ Stock Analysis page.